These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27310951)

  • 1. Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura.
    Nakamura K; Inokuchi R; Hiruma T; Ohshima K; Sonoo T; Tokunaga K; Doi K; Nakajima S
    Medicine (Baltimore); 2016 Jun; 95(24):e3712. PubMed ID: 27310951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in thrombotic thrombocytopenic purpura.
    Sadler JE; Moake JL; Miyata T; George JN
    Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
    Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective combination therapy of polymyxin-B direct hemoperfusion and recombinant thrombomodulin for septic shock accompanied by disseminated intravascular coagulation: a historical controlled trial.
    Yamato M; Minematsu Y; Fujii J; Mori K; Minato T; Miyagawa S; Fujimura R; Morikage N; Arata Y; Nakano C; Wada A; Ito T
    Ther Apher Dial; 2013 Oct; 17(5):472-6. PubMed ID: 24107274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries.
    Wada H; Mori Y; Shimura M; Hiyoyama K; Ioka M; Nakasaki T; Nishikawa M; Nakano M; Kumeda K; Kaneko T; Nakamura S; Shiku H
    Am J Hematol; 1998 Jul; 58(3):189-94. PubMed ID: 9662269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of endothelial damage and cardiac injury in a mouse model mimicking thrombotic thrombocytopenic purpura.
    Le Besnerais M; Favre J; Denis CV; Mulder P; Martinet J; Nicol L; Levesque H; Veyradier A; Kopić A; Motto DG; Coppo P; Richard V; Benhamou Y
    J Thromb Haemost; 2016 Oct; 14(10):1917-1930. PubMed ID: 27501520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation.
    Wada H; Ohiwa M; Kaneko T; Tamaki S; Tanigawa M; Shirakawa S; Koyama M; Hayashi T; Suzuki K
    Am J Hematol; 1992 Jan; 39(1):20-4. PubMed ID: 1311143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
    Furlan M; Lämmle B
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Link between von Willebrand factor multimers, relapses and coronary microcirculation in patients with thrombotic thrombocytopenic purpura in remission.
    Di Pasquale I; Budde U; Tona F; Bertomoro A; Lombardi AM; Famoso G; Bertozzi I; Dittmer R; Schneppenheim S; Fabris F
    Thromb Res; 2019 Jan; 173():42-47. PubMed ID: 30471507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification.
    Shenkman B; Einav Y
    Autoimmun Rev; 2014; 13(4-5):584-6. PubMed ID: 24418304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma von Willebrand Factor Antigen (vWF:AG) and thrombomodulin (TM) levels in Adult Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM).
    Zeigler ZR; Rosenfeld CS; Andrews DF; Nemunaitis J; Raymond JM; Shadduck RK; Kramer RE; Gryn JF; Rintels PB; Besa EC; George JN
    Am J Hematol; 1996 Dec; 53(4):213-20. PubMed ID: 8948657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
    Mori Y; Wada H; Okugawa Y; Tamaki S; Nakasaki T; Watanabe R; Gabazza EC; Nishikawa M; Minami N; Shiku H
    Clin Appl Thromb Hemost; 2001 Jan; 7(1):5-9. PubMed ID: 11190905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura.
    Deforche L; Tersteeg C; Roose E; Vandenbulcke A; Vandeputte N; Pareyn I; De Cock E; Rottensteiner H; Deckmyn H; De Meyer SF; Vanhoorelbeke K
    PLoS One; 2016; 11(8):e0160388. PubMed ID: 27479501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [From gene to disease; congenital thrombotic thrombocytopenic purpura due to mutations in the ADAMTS13 gene].
    Schiphorst RH; van de Kar NC; van den Heuvel LP
    Ned Tijdschr Geneeskd; 2003 Dec; 147(49):2422-4. PubMed ID: 14694551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.
    Abdelgawwad MS; Cao W; Zheng L; Kocher NK; Williams LA; Zheng XL
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2731-2743. PubMed ID: 30354235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors.
    Ouchi K; Takahashi S; Chikamatsu S; Ito S; Takahashi Y; Kawai S; Okita A; Kasahara Y; Okada Y; Imai H; Komine K; Saijo K; Takahashi M; Shirota H; Takahashi M; Gamoh M; Ishioka C
    Int J Clin Oncol; 2018 Aug; 23(4):790-798. PubMed ID: 29511940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study.
    Akahoshi T; Sugimori H; Kaku N; Tokuda K; Nagata T; Noda E; Morita M; Hashizume M; Maehara Y
    Eur J Trauma Emerg Surg; 2015 Oct; 41(5):531-8. PubMed ID: 26038004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura.
    Kopić A; Benamara K; Piskernik C; Plaimauer B; Horling F; Höbarth G; Ruthsatz T; Dietrich B; Muchitsch EM; Scheiflinger F; Turecek M; Höllriegl W
    J Thromb Haemost; 2016 Jul; 14(7):1410-9. PubMed ID: 27371116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.
    Furlan M
    Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):243-55. PubMed ID: 15030284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. von Willebrand factor and its cleaving protease ADAMTS13 balance in coronary artery vessels: Lessons learned from thrombotic thrombocytopenic purpura. A narrative review.
    Morici N; Cantoni S; Panzeri F; Sacco A; Rusconi C; Stucchi M; Oliva F; Cattaneo M
    Thromb Res; 2017 Jul; 155():78-85. PubMed ID: 28521259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.